Crinetics Pharmaceuticals Files 8-K on Shareholder Votes
Ticker: CRNX · Form: 8-K · Filed: Jun 10, 2024 · CIK: 1658247
| Field | Detail |
|---|---|
| Company | Crinetics Pharmaceuticals, Inc. (CRNX) |
| Form Type | 8-K |
| Filed Date | Jun 10, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: CRNX
TL;DR
CRNX filed an 8-K for a shareholder vote - check for governance updates.
AI Summary
Crinetics Pharmaceuticals, Inc. filed an 8-K on June 10, 2024, reporting on matters submitted to a vote of security holders as of June 7, 2024. The filing details information related to the company's corporate structure and its principal executive offices located in San Diego, California.
Why It Matters
This filing indicates that Crinetics Pharmaceuticals held a vote of its security holders, which could pertain to significant corporate decisions or governance matters.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote and does not appear to contain immediate negative financial or operational news.
Key Players & Entities
- Crinetics Pharmaceuticals, Inc. (company) — Registrant
- June 07, 2024 (date) — Date of earliest event reported
- June 10, 2024 (date) — Date of Report
- San Diego, California (location) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of Crinetics Pharmaceuticals' security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on June 07, 2024.
What is the principal executive office address for Crinetics Pharmaceuticals, Inc.?
The principal executive offices are located at 6055 Lusk Boulevard, San Diego, California, 92121.
What is the Commission File Number for Crinetics Pharmaceuticals, Inc.?
The Commission File Number for Crinetics Pharmaceuticals, Inc. is 001-38583.
What is the IRS Employer Identification Number for Crinetics Pharmaceuticals, Inc.?
The IRS Employer Identification Number for Crinetics Pharmaceuticals, Inc. is 26-3744114.
Filing Stats: 596 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-06-10 16:30:38
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CRNX Nasdaq Global Select
Filing Documents
- crnx-20240607.htm (8-K) — 51KB
- 0000950170-24-071354.txt ( ) — 163KB
- crnx-20240607.xsd (EX-101.SCH) — 24KB
- crnx-20240607_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. The annual meeting of stockholders of Crinetics Pharmaceuticals, Inc. (the "Company") was held online via live audio webcast on June 7, 2024 (the "Annual Meeting"). At the Annual Meeting, there were present, virtually or by proxy, holders of 78,744,364 shares of common stock, or approximately 86% of the total outstanding shares eligible to be voted. The final voting results with respect to each proposal presented at the Annual Meeting are as follows: Proposal One - Election of Directors The Company's stockholders approved the election of two Class III directors to the Board of Directors for three year terms to expire at the 2027 annual meeting of stockholders. The results of such vote were: Votes For Votes Withheld Broker Non-Votes Camille Bedrosian, M.D. 50,829,173 14,947,321 2,328,910 Wendell Wierenga, Ph.D. 50,300,772 15,475,722 2,328,910 Proposal Two - Ratification of Selection of Independent Registered Accounting Firm The Company's stockholders ratified the selection of BDO USA, P.C. as the Company's independent registered accounting firm for the fiscal year ending December 31, 2024. The results of such vote were: Votes For Votes Against Abstentions Broker Non-Votes 67,973,983 115,422 15,999 0 Proposal Three - Approval, on an advisory basis, of the compensation of the Company's named executive officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers. The results of such vote were: Votes For Votes Against Abstentions Broker Non-Votes 64,052,127 1,745,589 6,019 2,301,669
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Crinetics Pharmaceuticals, Inc. Date: June 10, 2024 By: /s/ R. Scott Struthers, Ph.D. R. Scott Struthers, Ph.D. President and Chief Executive Officer